Identification And Erradication Of Pre-malignant B Cells In The Prevention Of Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$607,771.00
Summary
B Cell Lymphoma is the most frequent type of non-Hodgkin lymphoma in adults and despite improved treatment, 40-50% of patients succumb to their disease. T cells are critical in the in the prevention B cell lymphoma development. In this project we aim to identify the earliest stages of B cell lymphoma and mechanisms of escape from T cell control with the ultimate aim to translate these findings to human studies to improve disease diagnosis, treatment and prognosis.
Effectiveness And Cost-effectiveness Of Systematic Screening For Lynch Syndrome (LS) In Australia
Funder
National Health and Medical Research Council
Funding Amount
$485,762.00
Summary
Lynch syndrome (LS) is an inherited condition that puts people at an increased risk of developing a range of cancers. We will use a detailed simulation model to evaluate the potential health benefits of testing new cases of colorectal, endometrial and ovarian cancers for LS, and whether this would be cost-effective. The aim is to identify LS-related cancer cases, so family members can be offered LS testing, and individuals found to have LS can be offered close observation/preventative surgery.
Low Dose Computed Tomography (LDCT) To Diagnose Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$3,032,884.00
Summary
This study aims to examine strategies for improving the effectiveness of lung cancer screening for reducing lung cancer deaths, and reducing the burden of the disease in the community. We will test the use of CT screening combined with a package of diagnostic measures, including the US NLST criteria, to determine if lung cancer nodules can be reliably detected at an earlier stage. Our aim in early detection is to also improve the potential for effective treatment approaches and health outcomes.
Modelling Epigenomic Change During Early Breast Carcinogenesis Using In Vitro And In Vivo Model Systems
Funder
National Health and Medical Research Council
Funding Amount
$743,360.00
Summary
Epigenetics describes how genes can be turned on and off without a change in the DNA sequence. Epigenetic changes are common and often occur early in cancer, but we do not know where or how epigenetic changes occur in cancer. In this proposal we will create the first detailed map of the epigenetic landscape of normal and cancer breast cells. These maps will allow us to predict where epigenetic lesions occur in breast cancer, which will have important diagnostic and therapeutic value for cancer t ....Epigenetics describes how genes can be turned on and off without a change in the DNA sequence. Epigenetic changes are common and often occur early in cancer, but we do not know where or how epigenetic changes occur in cancer. In this proposal we will create the first detailed map of the epigenetic landscape of normal and cancer breast cells. These maps will allow us to predict where epigenetic lesions occur in breast cancer, which will have important diagnostic and therapeutic value for cancer treatments.Read moreRead less
Targeting Activated Platelets: A Novel Innovative Approach For The Sensitive Detection And Therapeutic Targeting Of Various Cancers And Their Metastases
Funder
National Health and Medical Research Council
Funding Amount
$948,447.00
Summary
Early detection and selective therapy is critical for the survival of patients with cancer. We have shown in pilot experiments that platelets accumulate at the site of tumours and thus provide the opportunity to diagnose and localise cancer and its metastases. Based on this and also newly developed biotechnological tools we aim to develop multiple innovative imaging technologies. Furthermore, we will develop novel tumour-targeted and thus tumour site-specific, side-effect poor cancer treatments.
Establishment Of A Biomarker To Test Molecular Risk Of Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$834,448.00
Summary
Less than 20% of patients live 5 years after a diagnosis of gastric cancer (GC). This is due to the advanced stage at the time of diagnosis. We have no markers to monitor therapy of cancer. This proposal aims to use next generation sequencing to find specific genetic changes in a persons tumour that can be used to monitor therapy. We aim to use the same technology to group patients into high-risk or low risk for development of GC. This will allow specific screening only for those at high-risk.
Cervical Screening Participation And Outcomes For Indigenous Australian Women
Funder
National Health and Medical Research Council
Funding Amount
$601,546.00
Summary
Cervical cancer is much more common among Indigenous than other Australian women, however little is known about their cervical screening participation or outcomes. This study will use Pap Test Registers and other data sources to compare screening participation and outcomes for Indigenous and non-Indigenous women, and investigate whether cervical cancer incidence has decreased for Indigenous women in recent years, as it has done for non-Indigenous women in Australia.
Circulating Tumour DNA As A Marker Of Complete Pathological Response And Long Term Outcome For Locally Advanced Rectal Cancer Treated With Pre-operative Chemoradiotherapy
Funder
National Health and Medical Research Council
Funding Amount
$613,183.00
Summary
Rectal cancers are often treated by chemoradiotherapy (CRT) followed by surgery which may result in long-term stoma. A significant proportion of these patients can achieve complete remission to CRT alone. This project will assess the accuracy of a promising blood marker (circulating tumour DNA) for predicting response to treatment in patients with rectal cancer undergoing CRT. If confirmed to be a reliable marker, this test could be used to select patients who may be able to avoid or delay surge ....Rectal cancers are often treated by chemoradiotherapy (CRT) followed by surgery which may result in long-term stoma. A significant proportion of these patients can achieve complete remission to CRT alone. This project will assess the accuracy of a promising blood marker (circulating tumour DNA) for predicting response to treatment in patients with rectal cancer undergoing CRT. If confirmed to be a reliable marker, this test could be used to select patients who may be able to avoid or delay surgery.Read moreRead less
Prospective Methylation Biomarker Validation Study In Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$528,281.00
Summary
Lung cancer is a major public health burden with increasing incidence every year. Despite advances, the biology of lung cancer associated with its recurrence either local or distant, with non-smoking lung cancer subtypes and asbestos-related lung cancer remains unexplored.
Enterovirus, Vitamin D Status And Inflammation At The Clinical Onset Of Type 1 Diabetes In Childhood
Funder
National Health and Medical Research Council
Funding Amount
$410,542.00
Summary
Type 1 diabetes is a serious disease that is increasing in incidence among Australian children. This project will build on an exsisting study to provide new information on the role of enteroviral infection, vitamin D status and the associated inflammatory changes in blood at the onset of disease.